1.ENPP1/PC-1 gene K121Q polymorphism is associated with obesity in European adult populations: evidence from a meta-analysis involving 24,324 subjects.
RuoQi WANG ; DongHao ZHOU ; Bo XI ; XiuShan GE ; Ping ZHU ; Bo WANG ; MingAi ZHOU ; YuBei HUANG ; JunTing LIU ; Yang YU ; ChunYu WANG
Biomedical and Environmental Sciences 2011;24(2):200-206
OBJECTIVEFindings from the previous studies have suggested a relationship between ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP-1) or plasma cell membrane glycoprotein 1 (PC-1) gene single nucleotide polymorphism (K121Q, rs1044498) and genetic susceptibility to obesity. However, such relationship is not reproduced by some currently available studies. In this context, the present study is aimed to quantitatively analyze the association of K121Q variant with obesity in all published case-control studies in European adult populations.
METHODSPublished literature from PubMed, EMBASE, and ISI web of science databases were retrieved. The studies evaluating the association of ENPP1/PC1 gene K121Q polymorphism with obesity were included, in which sufficient data were presented to calculate the odds ratio (OR) with 95% confidence intervals (CIs).
RESULTSTen case-control studies meeting the inclusion criteria identified a total of 24,324 subjects including 11,372 obese and 12,952 control subjects. The meta-analysis results showed a statistically significant association of K121Q with obesity [OR (95%CI): 1.25 (1.04-1.52) P=0.021] under a recessive model of inheritance (QQ vs. KK+KQ) without heterogeneity or publication bias.
CONCLUSIONSThe results from the present study have indicated that ENPP1/PC1 Q121 variant may increase the risk of obesity and that more well-designed studies based on a larger population will be required to further evaluate the role of ENPP1/PC1 gene K121Q polymorphism in obesity and other related metabolic syndromes.
Europe ; epidemiology ; Genetic Predisposition to Disease ; Humans ; Obesity ; epidemiology ; genetics ; Odds Ratio ; Phosphoric Diester Hydrolases ; genetics ; Polymorphism, Genetic ; Pyrophosphatases ; genetics ; Risk Factors
2.Challenges and countermeasures of breast surgery graduate teaching
Lei ZHONG ; Jiarui ZHANG ; Yujie SHI ; Ruoqi WANG ; Xiaoyan ZHANG ; Hangyu LIU
Chinese Journal of Medical Education Research 2021;20(11):1275-1279
Accompanied by the rapid improvement of clinical diagnosis and treatment technology and the needs of scientific research, the training of higher professional talents represented by breast surgery postgraduates is facing many challenges. Based on the above background, this study puts forward the new teaching mode combining online and offline, involving evidence-based medicine guidelines, strengthening the aesthetic concept and humanistic teaching quality into the breast surgery teaching system to improve the teaching concept and teaching mode. Through the intuitive information teaching means and clinical case analysis, the students' independent learning and thinking ability can be cultivated. Finally, we look forward to improving the scientific research level and the cultivation of breast surgeons with outstanding comprehensive ability and medical humanistic quality from the optimization of teaching modes.
3.Research progress in the treatment of intestinal flora in diabetic nephropathy
Yizhuo FENG ; Qingxia LI ; Xueqian LIU ; Lu BAI ; Zhuomin QU ; Ruoqi LIU ; Lingxia ZHAO
Journal of Chinese Physician 2024;26(11):1753-1757
Diabetic nephropathy (DN) is a clinical syndrome characterized by persistent proteinuria and progressive decline in renal function, and is one of the microvascular complications of diabetes. With the in-depth understanding of the pathogenesis of DN, the role of intestinal flora imbalance in the disease has been found clinically. This suggests that restoring the host′s healthy gut flora may be a means of improving DN. In fact, recent studies have shown that many of the drugs currently used to treat DN affect gut microbiota composition. In this review, intestinal flora is regarded as one of the main factors affecting the development of DN, and DN therapy targeting intestinal flora is summarized to provide new ideas for the diagnosis and treatment of DN.
4.Research advances in toxicity of uranium in vivo and its new chelators
Wenhua ZHOU ; Jinjin YING ; Jie GAO ; Huan LIU ; Ruoqi WANG ; Jianguo LI
Chinese Journal of Radiological Health 2022;31(3):379-385
Uranium is an important radioactive actinide in nature and an important nuclear material in nuclear industry. After uranium is accidentally released into the environment, it enters the body through the respiratory tract, the digestive tract, and other ways, then enters the circulation system through blood, and is finally mainly deposited in the kidney and bone, causing a certain degree of toxicity. Therefore, efficient low-toxicity chelators are an important way to reduce radionuclide pollution, radiation damage, and chemical toxicity. This article reviews uranium deposition and harm, the detoxification mechanism of uranium chelators, and the research advances in uranium chelators and points out the development trend of uranium chelators.
5.Analysis on the Difference of Median Survival Time of Advanced Pancreatic Cancer Patients with Different Traditional Chinese Medicine Syndromes and Intervention Times of Chinese Herbal Medicine:A Retrospective Study
Jing WANG ; Chaoyong WU ; Bin LIU ; Ruoqi ZHANG ; Rui MIAO ; Xiuwei GUO ; Peitong ZHANG
Journal of Traditional Chinese Medicine 2024;65(22):2332-2337
ObjectiveTo observe the distribution of traditional Chinese medicine (TCM) syndrome types in advanced pancreatic cancer patients, and explore the association between median survival time and different TCM syndromes and different intervention times of Chinese herbal medicine (CHM). MethodsThe clinical data of 136 advanced pancreatic cancer patients who have received CHM for more than 3 months were collected retrospectively, including gender, age, family history, smoking history, drinking history, location of disease, lymph node metastasis, multiple distant metastasis, western medicine treatment methods, TCM diagnosis and treatment information, and survival time. The Kaplan-Meier (KM) estimator was used, and the median survival time of patients was calculated. The TCM syndrome type of each patient was judged, and the main single syndrome types and compound syndrome types were summarized. The median survival time was compared among different compound syndrome types. The patients were further divided into the group of those having received CHM ≥6 months and those having received CHM <6 months. Whether receiving CHM ≥6 months was taken as the grouping variable, while the matching variables were age, gender, family history, smoking history, drinking history, location of disease, lymph node metastasis, multiple distant metastasis, surgery, chemotherapy, and radiotherapy when propensity score matching was performed, and the difference in median survival time between the two groups of patients before and after matching was compared. ResultsFor 136 cases of advanced pancreatic cancer, the top five single syndromes were spleen qi deficiency, liver blood stasis, liver qi stagnation, spleen dampness, and liver heat. The main compound types were liver constraint, spleen deficiency and blood stasis syndrome, liver-gallbladder damp-heat and blood stasis syndrome, liver constraint, qi stagnation and spleen deficiency syndrome, spleen-stomach yang deficiency and blood stasis syndrome, and spleen deficiency and dampness-heat internal accumulation syndrome. The overall median survival time before and after matching was 12.47 (7.70,17.10) months and 13.77 (8.83,17.20) months, respectively, and was significantly higher in the group treated with CHM ≥ 6 months than that treated with CHM <6 months (P<0.05). Among the 136 patients before matching, the median survival time of patients with spleen deficiency and dampness-heat internal accumulation syndrome was longest [16.23 (14.17,19.40) months], while that of patients with spleen-stomach yang deficiency and blood stasis syndrome was the shortest [7.33 (5.80,12.83) months]. For patients with liver constraint, spleen deficiency and blood stasis syndrome, liver-gallbladder damp-heat and blood stasis syndrome, and spleen-stomach yang deficiency and blood stasis syndrome, those having received CHM ≥ 6 months have much longer median survival time than those having received CHM <6 months (P<0.05). Among the 108 patients after matching, the median survival time of those with spleen deficiency and dampness-heat internal accumulation syndrome was the longest [15.23 (7.67,18.27) months], while that of spleen-stomach yang deficiency and blood stasis syndrome was the shortest [8.80 (6.90,16.17) months]. For patients with liver-gallbladder dampness-heat and blood stasis syndrome and spleen-stomach yang deficiency and blood stasis syndrome, the median survival time was higher in the group treated with CHM ≥ 6 months treated with CHM <6 months (P<0.05). ConclusionAfter treatment with CHM, advanced pancreatic cancer patients with spleen deficiency and damp-heat internal accumulation had a better prognosis, while those with spleen-stomach yang deficiency and blood stasis had a worse prognosis. Treatment with CHM ≥ 6 months could extend the median survival of advanced pancreatic cancer patients with liver-gallbladder damp-heat and blood stasis syndrome and spleen-stomach yang deficiency and blood stasis syndrome.